Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 114379
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.114379
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.114379
Anti-EGFR treatment resistance in patients with wild-type RAS metastatic colorectal cancer: Three case reports
Jing Wang, Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Qian Pei, Department of Gastrointestinal Surgery, The Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Nan-Hui Yu, Department of Gastrointestinal Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Co-first authors: Jing Wang and Qian Pei.
Author contributions: Wang J and Pei Q contributed to manuscript writing, data collection. and data analysis; Yu NH contributed to study design and manuscript editing. All authors have read and approve the final manuscript. Wang J and Pei Q contributed equally to this work.
Supported by the Natural Science Foundation of Hunan Province (2023JJ40977).
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: This article does not involve any conflict of competing interest.
CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).
Corresponding author: Nan-Hui Yu, PhD, Associate Professor, Department of Gastrointestinal Surgery, The Second Xiangya Hospital, Central South University, No. 139 Renmin Middle Road, Changsha 410011, Hunan Province, China. yunanhui@csu.edu.cn
Received: September 18, 2025
Revised: October 24, 2025
Accepted: January 22, 2026
Published online: March 15, 2026
Processing time: 175 Days and 20 Hours
Revised: October 24, 2025
Accepted: January 22, 2026
Published online: March 15, 2026
Processing time: 175 Days and 20 Hours
Core Tip
Core Tip: In this study, 3 wild-type RAS metastatic colorectal cancer patients with anti-EGFR resistance were analyzed. Key findings: Acquired resistance is associated with KRAS mutation/HER-2 amplification and primary resistance is associated with metastatic KRAS mutation (tumor heterogeneity). These findings suggest essential genetic profiling